gsk201603016k2.htm

SECURITIES AND EXCHANGE COMMISSION 

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of 

the Securities Exchange Act of 1934

For period ending March 2016

(Name of registrant) 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 

Form 20-F x Form 40-F 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Vesting of conditional share awards under the

GlaxoSmithKline Share Value Plan

This notification sets out the vesting of an award over American Depositary Shares (ADS) in GlaxoSmithKline plc, made in 2013 under the GlaxoSmithKline Share Value Plan (SVP), which was conditional on continued employment with the GlaxoSmithKline group.

The restricted period for the 2013 SVP awards has now ended and the award made to the connected person of a Person Discharging Managerial Responsibility (PDMR) vested on 28 February 2016. Details are given in the table below.

Name of Director / PDMR	Name of connected person	Number of ADS vested
Dr M Slaoui*	Dr K Slaoui	2,990

* Denotes an Executive Director

The Company and the above individual were advised of this transaction on 29 February 2016.

The closing price of an ADS of GlaxoSmithKline plc on 26 February 2015, the business day prior to vesting, was US$39.14.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).

V A Whyte

Company Secretary

1 March 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 

Date: 01 March, 2016

----------------------

Authorised Signatory for and on

behalf of GlaxoSmithKline plc